Inhaled antibiotics: Dry or wet?

European Respiratory Journal

Volumn 44, Issue 5, 2014, Pages 1308-1318

  Tiddens, Harm A W M ^a,b   Bos, Aukje C ^a,b   Mouton, Johan W ^b   Devadason, Sunalene ^c   Janssens, Hettie M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; AZTREONAM; BRONCHODILATING AGENT; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIMETHATE; COLISTIN; CORTICOSTEROID; DORNASE ALFA; TOBRAMYCIN; VANCOMYCIN; AEROSOL; ANTIINFECTIVE AGENT;

AEROSOL; ANTIBIOTIC THERAPY; CYSTIC FIBROSIS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SPUTUM LEVEL; DRUG TARGETING; DRY POWDER INHALER; HUMAN; JET NEBULIZER; LOADING DRUG DOSE; LUNG DEPOSITION; MESH NEBULIZER; METERED DOSE INHALER; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; NEBULIZER; NEBULIZER KIT; OUTCOME ASSESSMENT; PARTICLE SIZE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT PARAMETERS; REVIEW; SMART NEBULIZER; SPRAY DRYING; TREATMENT RESPONSE; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; AZTREONAM; COLISTIN; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRY POWDER INHALERS; HUMANS; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84926333134     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00090314     Document Type: Review

References (52)

1. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180: 146-152.
2. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368: 1963-1970.
3. Tiddens HAWM, Donaldson SH, Rosenfeld M, et al. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol 2010; 45: 107-117.
4. Loeve M, Hop WC, de Bruijne M, et al. Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2012; 185: 1096-1103.
5. Littlewood JM, Miller MG, Ghoneim AT, et al. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985; 1: 865.
6. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999; 28: 159-166.
7. Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial. Thorax 2010; 65: 286-291.
8. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
9. Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 2014; 13: Suppl. 1, S23-S42.
10. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23-30.
11. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-1232.
12. Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002; 33: 269-276.
13. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-984.
14. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-9.
15. Tiddens HA, De Boeck K, Clancy JP, et al. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. J Cyst Fibros 2014 [In press DOI:10.1016/j.jcf.2014.06.003].
16. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-928.
17. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19: 831-8.
18. Conole D, Keating GM. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs 2014; 74: 377-387.
19. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10: 54-61.
20. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68: 344-350.
21. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107-1115.
22. Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther 2013; 35: 1571-1581.
23. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 183: 1510-1516.
24. Gaspar MC, Couet W, Olivier JC, et al. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis 2013; 32: 1231-1252.
25. Park CW, Li X, Vogt FG, et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 2013; 455: 374-392.
26. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008; 21: 71-76.
27. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 1503-10.
28. Tiddens HAWM. Facts and fiction in inhalation therapy. Ital J Pediatr 2003; 29: 39-43.
29. de Jongh FH, Rinkel MJ, Hoeijmakers HW. Aerosol deposition in the upper airways of a child. J Aerosol Med 2006; 19: 279-289.
30. Laube BL, Jashnani R, Dalby RN, et al. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000; 118: 1069-1076.
31. Laube BL, Geller DE, Lin TC, et al. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir Care 2005; 50: 1438-1444.
32. Bos AC, vos WG, De Backer JW, et al. Airways surface liquid consentrations of aztreonam lysine for inhalation in children with cystic fibrosis: a modelling study. J Cyst Fibros 2013; 12: Suppl. 1, S98.
33. Fouras A, Allison BJ, Kitchen MJ, et al. Altered lung motion is a sensitive indicator of regional lung disease. Ann Biomed Eng 2012; 40: 1160-1169.
34. Vinchurkar S, Backer LD, Vos W, et al. A case series on lung deposition analysis of inhaled medication using functional imaging based computational fluid dynamics in asthmatic patients: effect of upper airway morphology and comparison with in vivo data. Inhal Toxicol 2012; 24: 81-88.
35. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123: 1495-1502.
36. Perry JD, Laine L, Hughes S, et al. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother 2008; 61: 1057-1061.
37. Fothergill JL, Mowat E, Ledson MJ, et al. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J Med Microbiol 2010; 59: 472-481.
38. Daniels T, Mills N, Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev 2013; 4: CD007639.
39. Esposito-Festen JE, Ates B, van Vliet FJM, et al. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. J Aerosol Med 2004; 17: 1-6.
40. Smaldone GC, Sangwan S, Shah A. Facemask design, facial deposition, and delivered dose of nebulized aerosols. J Aerosol Med 2007; 20: Suppl. 1, S66-S75.
41. Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994; 7: 2185-2191.
42. Nikander K, Prince I, Coughlin S, et al. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of 99mTc-DTPA. J Aerosol Med Pulm Drug Deliv 2010; 23: Suppl. 1, S37-S43.
43. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-1331.
44. Bakker EM, Volpi S, Salonini E, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2011; 38: 1328-35.
45. McNamara PS, McCormack P, McDonald AJ, et al. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros 2009; 8: 258-263.
46. Bakker EM, Borsboom GJ, van der Wiel-Kooij EC, et al. Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker. Pediatr Pulmonol 2013; 48: 1081-1088.
47. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012; 47: 523-533.
48. Blau H, Mussaffi H, Mei Zahav M, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007; 33: 491-5.
49. Rottier BL, van Erp CJ, Sluyter TS, et al. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009; 22: 263-269.
50. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv 2011; 24: 175-182.
51. Tiddens HAWM, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med 2006; 19: 456-465.
52. Robinson TE, Leung AN, Chen X, et al. Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Pediatr Pulmonol 2009; 44: 1107-1117.